|
1
|
Bielack SS: Osteosarcoma: Time to move on?
Eur J Cancer. 46:1942–1945. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng DD, Yu T, Hu T, Yao M, Fan CY and
Yang QC: MiR-542-5p is a negative prognostic factor and promotes
osteosarcoma tumorigenesis by targeting HUWE1. Oncotarget.
6:42761–42772. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wagle S, Park SH, Kim KM, Moon YJ, Bae JS,
Kwon KS, Park HS, Lee H, Moon WS, Kim JR and Jang KY: DBC1/CCAR2 is
involved in the stabilization of androgen receptor and the
progression of osteosarcoma. Sci Rep. 5:131442015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Damron TA, Ward WG and Stewart A:
Osteosarcoma, chondrosarcoma and Ewing's sarcoma: National Cancer
Data Base Report. Clin Orthop Relat Res. 459:40–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Byun BH, Kong CB, Lim I, Kim BI, Choi CW,
Song WS, Cho WH, Jeon DG, Koh JS, Lee SY and Lim SM: Comparison of
(18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection
of bone metastasis in osteosarcoma. Skeletal Radiol. 42:1673–1681.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dirik Y, Çınar A, Yumrukçal F and Eralp L:
Popliteal lymph node metastasis of tibial osteoblastic
osteosarcoma. Int J Surg Case Rep. 5:840–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yanagawa T, Saito K and Takagishi K: Risk
factors for lymphatic metastasis of malignant bone and soft-tissue
tumors: A retrospective cohort study of 242 patients. Medicine
(Baltimore). 93:e2252014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu H, Tang J, Tang M and Cai H:
Upregulation of SOX9 in osteosarcoma and its association with tumor
progression and patients' prognosis. Diagn Pathol. 8:1832013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bi Y, Jing Y and Cao Y: Overexpression of
miR-100 inhibits growth of osteosarcoma through FGFR3. Tumour Biol.
36:8405–8411. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang W, Zhou X and Wei M: MicroRNA-144
suppresses osteosarcoma growth and metastasis by targeting ROCK1
and ROCK2. Oncotarget. 6:10297–10308. 2015.PubMed/NCBI
|
|
11
|
Rainusso N, Wang LL and Yustein JT: The
adolescent and young adult with cancer: State of the art-bone
tumors. Curr Oncol Rep. 15:296–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gorlick R, Anderson P, Andrulis I, Arndt
C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D,
et al: Biology of childhood osteogenic sarcoma and potential
targets for therapeutic development: Meeting summary. Clin Cancer
Res. 9:5442–5453. 2003.PubMed/NCBI
|
|
13
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation
and outcome of patients treated on neoadjuvant cooperative
osteosarcoma study group protocols. J Clin Oncol. 21:2011–2018.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wan J and Zhang X, Liu T and Zhang X:
Strategies and developments of immunotherapies in osteosarcoma.
Oncol Lett. 11:511–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kamachi Y and Kondoh H: Sox proteins:
Regulators of cell fate specification and differentiation.
Development. 140:4129–4144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wegner M: From head to toes: The multiple
facets of Sox proteins. Nucleic Acids Res. 27:1409–1420. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bowles J, Schepers G and Koopman P:
Phylogeny of the SOX family of developmental transcription factors
based on sequence and structural indicators. Dev Biol. 227:239–255.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang
Y, Zhao J, McCrae MA and Zhuang H: Aberrant expression of microRNA
155 may accelerate cell proliferation by targeting sex-determining
region Y box 6 in hepatocellular carcinoma. Cancer. 118:2431–2442.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo X, Yang M, Gu H, Zhao J and Zou L:
Decreased expression of SOX6 confers a poor prognosis in
hepatocellular carcinoma. Cancer Epidemiol. 37:732–736. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin YR, Tang H, Xie F, Liu H, Zhu Y, Ai J,
Chen L, Li Y, Kwong DL, Fu L and Guan XY: Characterization of
tumor-suppressive function of SOX6 in human esophageal squamous
cell carcinoma. Clin Cancer Res. 17:46–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cantù C, Ierardi R, Alborelli I, Fugazza
C, Cassinelli L, Piconese S, Bosè F, Ottolenghi S, Ferrari G and
Ronchi A: Sox6 enhances erythroid differentiation in human
erythroid progenitors. Blood. 117:3669–3679. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iguchi H, Urashima Y, Inagaki Y, Ikeda Y,
Okamura M, Tanaka T, Uchida A, Yamamoto TT, Kodama T and Sakai J:
SOX6 suppresses cyclin D1 promoter activity by interacting with
beta-catenin and histone deacetylase 1, and its down-regulation
induces pancreatic beta-cell proliferation. J Biol Chem.
282:19052–19061. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sannino G, Armbruster N, Bodenhöfer M,
Haerle U, Behrens D, Buchholz M, Rothbauer U, Sipos B and Schmees
C: Role of BCL9 L in transforming growth factor-β (TGF-β)-induced
epithelial-to-mesenchymal-transition (EMT) and metastasis of
pancreatic cancer. Oncotarget. 7:73725–73738. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang D, Han S, Wang X, Peng R and Li X:
SOX5 promotes epithelial-mesenchymal transition and cell invasion
via regulation of Twist1 in hepatocellular carcinoma. Med Oncol.
32:4612015.PubMed/NCBI
|
|
26
|
Huang J and Guo L: Knockdown of SOX9
Inhibits the Proliferation, Invasion, and EMT in Thyroid Cancer
Cells. Oncol Res. 25:167–176. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Medici D, Hay ED and Olsen BR: Snail and
Slug promote epithelial-mesenchymal transition through
beta-catenin-T-cell factor-4-dependent expression of transforming
growth factor-beta3. Mol Biol Cell. 19:4875–4887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alves CC, Carneiro F, Hoefler H and Becker
KF: Role of the epithelial-mesenchymal transition regulator Slug in
primary human cancers. Front Biosci (Landmark Ed). 14:3035–3050.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kojc N, Zidar N, Gale N, Poljak M, Fujs
Komlos K, Cardesa A, Höfler H and Becker KF: Transcription factors
Snail, Slug, Twist, and SIP1 in spindle cell carcinoma of the head
and neck. Virchows Arch. 454:549–555. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Preca BT, Bajdak K, Mock K, Lehmann W,
Sundararajan V, Bronsert P, Matzge-Ogi A, Orian-Rousseau V,
Brabletz S, Brabletz T, et al: A novel ZEB1/HAS2 positive feedback
loop promotes EMT in breast cancer. Oncotarget. 8:11530–11543.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Z and Wang Y: MiR-96 targets SOX6 and
promotes proliferation, migration and invasion of hepatocellular
carcinoma. Biochem Cell Biol. July 17–2017.doi:
10.1139/bcb-2017-0183. (Epub ahead of print). View Article : Google Scholar
|
|
32
|
Li YC, Li CF, Chen LB, Li DD, Yang L, Jin
JP and Zhang B: MicroRNA-766 targeting regulation of SOX6
expression promoted cell proliferation of human colorectal cancer.
Onco Targets Ther. 8:2981–2988. 2015. View Article : Google Scholar : PubMed/NCBI
|
